363 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
Conditions: Uterine Cervical Cancer;   Diffusion-weighted MRI;   Recurrence
Intervention: Procedure: Diffusion weighted MRI (DW- MRI)
22 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Conditions: Stage IA Uterine Sarcoma;   Stage IB Uterine Sarcoma;   Stage IC Uterine Sarcoma;   Stage IIA Uterine Sarcoma;   Stage IIB Uterine Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Other: laboratory biomarker analysis
23 Unknown  Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
Condition: Endometrial Cancer
Interventions: Genetic: microarray analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: study of socioeconomic and demographic variables
24 Recruiting Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed By Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Conditions: Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
25 Not yet recruiting ADXS11-001 High Dose HPV+ Cervical Cancer
Conditions: Effects of Immunotherapy;   Metastatic/Recurrent Cervical Cancer;   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Intervention: Biological: ADXS11-001
26 Recruiting Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Conditions: Mixed Muellerian Cancer;   Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Carcinosarcoma
Interventions: Drug: Carboplatin;   Drug: Olaparib
27 Recruiting Lymphedema After Primary Surgery for Endometrial Cancer
Conditions: Carcinoma of the Endometrium;   Hysterectomy;   Lymphadenectomy
Intervention: Procedure: Lymphadenectomy
28 Recruiting Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Intervention: Radiation: Radiotherapy
29 Recruiting Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Conditions: Endometrial Atypical Hyperplasia;   Endometrial Adenocarcinoma
Interventions: Drug: Megestrol acetate and metformin;   Drug: Megestrol acetate
30 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
31 Recruiting The Hysteroscopic Morcellator (HM).
Conditions: Large Intrauterine Polyps;   Smaller Type 0 and 1 Myomas;   Residual Placental Tissue
Interventions: Procedure: Hysteroscopic morcellator;   Procedure: Resectoscope
32 Recruiting Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Conditions: Endometrial Adenocarcinomas;   Neuroendocrine Tumors;   Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)
Interventions: Drug: lurbinectedin (PM01183);   Drug: Doxorubicin
33 Not yet recruiting Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
Conditions: Atypical Endometrial Hyperplasia;   Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Stage IA Endometrial Carcinoma;   Stage IB Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: megestrol acetate;   Device: levonorgestrel-releasing intrauterine system;   Other: laboratory biomarker analysis;   Other: questionnaire administration
34 Recruiting Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Condition: Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Interventions: Drug: Pazopanib plus Gemcitabine;   Drug: Pazopanib
35 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
36 Recruiting Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery
Conditions: Asherman Syndrome;   Endometrial Polyp;   Uterine Myoma
Intervention: Drug: INTERCOAT administration
37 Recruiting Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women
Conditions: Endometrial Polyp.;   Malignant and Pre-malignant Changes in the Polyp
Intervention: Procedure: Hysteroscopic polypectomy
38 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Radiation: brachytherapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin
39 Recruiting Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function
Condition: Corpus Uteri Carcinoma
Intervention:
40 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: questionnaire administration

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years